First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
This acquisition marks Max Healthcare's entry into Lucknow
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
Late-stage Fabhalta development program ongoing in multiple complement-mediated conditions
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
Covaris is a global leader in the development and deployment of end-to-end solutions for high-throughput genomic and proteomic analysis
Multi-ethnic innovation helps all complexions appear clearer and more uniform
The acquisition will add 20,000 litres of installed biologics drug substance manufacturing capacity for Syngene
Subscribe To Our Newsletter & Stay Updated
